|1.||Kobayashi, Hisataka: 3 articles (01/2009 - 09/2006)|
|2.||Choyke, Peter L: 3 articles (01/2009 - 09/2006)|
|3.||Koyama, Yoshinori: 2 articles (04/2007 - 09/2006)|
|4.||Urano, Yasuteru: 2 articles (04/2007 - 09/2006)|
|5.||Hama, Yukihiro: 2 articles (04/2007 - 09/2006)|
|6.||van Amerongen, Aart: 1 article (09/2013)|
|7.||Norde, Willem: 1 article (09/2013)|
|8.||Moers, Antoine: 1 article (09/2013)|
|9.||Mujawar, Liyakat Hamid: 1 article (09/2013)|
|10.||Neves, André A: 1 article (08/2011)|
01/01/2009 - "Tumor-specific detection of an optically targeted antibody combined with a quencher-conjugated neutravidin "quencher-chaser": a dual "quench and chase" strategy to improve target to nontarget ratios for molecular imaging of cancer."
04/01/2003 - "This rapid removal by the reticuloendothelial system (RES) permitted the determination of the tumor efflux kinetics due to negligible tumor influx after neutravidin injection. "
08/01/2011 - "At 24 h after administration of NeutrAvidin, labeled with either a far-red fluorophore or (111)In, there was a significant azido-labeled N-acetyl-mannosamine-dependent increase in tumor-to-tissue contrast, which was detected using optical imaging or single-photon-emission computed tomography (SPECT), respectively. "
04/15/2007 - "This two-step activation paradigm (pretargeting followed by neutravidin-biotin binding with an attached activatable fluorophore) could be useful in tumor-specific molecular imaging of various targets to guide surgical resections."
04/15/2007 - "Following this, a second agent, neutravidin-BODIPY-FL fluorescent conjugate, is given and binds to the previously targeted antibody, resulting in an approximately 10-fold amplification of the optical fluorescence signal, leading to high tumor-to-background ratios. "
11/15/2004 - "Biotinylated PCR products containing the SNP (The SNP summary web site: ) (mutant) and those containing no mutation (wild-type) were brought onto the chips coated with NeutrAvidin using non-contact spotting. "
11/01/2008 - "Using Flexchip protein A/G and neutravidin capturing surfaces, we demonstrate that our new microfluidic spotter requires 1000 times less concentrated antibodies and biotinylated ligands than is required for pin spotting. "
|5.||Neoplasm Metastasis (Metastasis)
|1.||Staphylococcal Protein A (A, Protein)
|4.||4,4- difluoro- 4- bora- 3a,4a- diaza- s- indacene
|8.||Epidermal Growth Factor Receptor (EGF Receptor)